Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells include coupling an alternating polarity (AP) magnetic field generator to a target body area and applying an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells include coupling an alternating polarity (AP) magnetic field generator to a target body area and applying an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

A breakaway connector apparatus including a housing and a breakaway component is configured for attachment directly to a needle-free fitting on an intravenous line. The breakaway connector apparatus includes only one valve. The apparatus is configured to open both the valve and a seal on the needle-free fitting when the breakaway component is attached to the needle-free fitting. When tension is applied to the connector, the breakaway component is configured to detach from the apparatus while remaining attached to the needle-free fitting, thereby closing the valve on the apparatus and also closing the seal on the needle-free fitting. In some embodiments, the breakaway connector apparatus includes one or more securing arms and one or more corresponding securing bars to prevent re-connection of the apparatus following disengagement of the breakaway component from the apparatus.

A breakaway connector apparatus including a housing and a breakaway component is configured for attachment directly to a needle-free fitting on an intravenous line. The breakaway connector apparatus includes only one valve. The apparatus is configured to open both the valve and a seal on the needle-free fitting when the breakaway component is attached to the needle-free fitting. When tension is applied to the connector, the breakaway component is configured to detach from the apparatus while remaining attached to the needle-free fitting, thereby closing the valve on the apparatus and also closing the seal on the needle-free fitting. In some embodiments, the breakaway connector apparatus includes one or more securing arms and one or more corresponding securing bars to prevent re-connection of the apparatus following disengagement of the breakaway component from the apparatus.

A resin hollow needle includes a distal end section including a puncture end portion, a large-diameter section having a diameter greater than that of the distal end section, a tapered section that is located between the large-diameter section and the distal end section, and a hub section. The distal end section includes a hole that is provided on a proximal end side in comparison to a distal end and on a distal end side of the tapered section, and communicates with the inside and the outside of a hollow needle, and a tapered puncture end portion. The distal end section has a total length of 7 to 14 mm and a maximum outer diameter of 1.5 to 3.0 mm. The tapered section has a length of 0.3 to 4.7 mm and a taper angle of 10° to 50°. The large-diameter section has a length of 4 mm or greater, and a distal end outer diameter that is greater than the maximum outer diameter of the distal end section by 0.6 to 3.0 mm.

A connector for forming a fluid flow pathway by connection with a reciprocal connector. Both the connector and reciprocal connector include a fluid flow blockage part sheathed within an axially compressible sheath part. A first bearing surface receives an urging force to retract the blockage part axially along the sheath part. A terminal end of the sheath part defines a second bearing surface containing a fluid flow opening with the fluid flow blockage part retractably therein. A first chassis part includes a first catch part. A second chassis part includes a second catch part and a third bearing surface spaced from the second catch part along the second chassis part. Retraction of the blockage part forms a fluid flow pathway not sooner than immediately when the openings meet to allow fluid transfer the openings avoiding fluid leakage between connected connectors.

A drug delivery system for injecting a medicament may include a housing defining a cavity, a container received within the cavity and configured to receive a medicament with the container including a closure, a valve assembly received within the cavity and including a piercing member configured to pierce the closure of the container, and a connector arrangement provided between the container and the valve assembly, the connector arrangement movable between a first, pre-use position maintaining sterility between the closure of the container and the valve assembly and a second, use position permitting fluid communication between the container and the valve assembly.

A drug delivery system for injecting a medicament may include a housing defining a cavity, a container received within the cavity and configured to receive a medicament with the container including a closure, a valve assembly received within the cavity and including a piercing member configured to pierce the closure of the container, and a connector arrangement provided between the container and the valve assembly, the connector arrangement movable between a first, pre-use position maintaining sterility between the closure of the container and the valve assembly and a second, use position permitting fluid communication between the container and the valve assembly.

A system for the closed transfer of fluids that provides substantially leak-proof sealing and pressure equalization during engagement of a cannula with a vial, during transfer of a substance from a vial chamber to a barrel chamber via the cannula, and during disengagement of the cannula from the vial is disclosed. The leak-proof sealing of the system substantially prevents leakage of both air and liquid during use of the system. The system of the present disclosure also permits pressure equalization between a vial and the system when the system is attached to the vial. The system is compatible with a needle and syringe assembly for accessing a medication contained within a vial for administering the medication to a patient.

A system for the closed transfer of fluids that provides substantially leak-proof sealing and pressure equalization during engagement of a cannula with a vial, during transfer of a substance from a vial chamber to a barrel chamber via the cannula, and during disengagement of the cannula from the vial is disclosed. The leak-proof sealing of the system substantially prevents leakage of both air and liquid during use of the system. The system of the present disclosure also permits pressure equalization between a vial and the system when the system is attached to the vial. The system is compatible with a needle and syringe assembly for accessing a medication contained within a vial for administering the medication to a patient.